# Extension Study of MT-1303

> **NCT01890655** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 367 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** MT-1303-Low
- **DRUG:** MT-1303-Middle
- **DRUG:** MT-1303-High

## Key facts

- **NCT ID:** NCT01890655
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2016-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890655, "Extension Study of MT-1303". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01890655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*